8
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T1803 | GNF-5 | GNF 5 | SARS-CoV , Bcr-Abl |
GNF-5 is a specific non-ATP competitive inhibitor of Bcr-Abl (IC50: 0.22±0.1 uM, Wild-type Abl). It is an analog of GNF-2 with improved pharmacokinetic properties. | |||
T3196 | GNF-7 | GNF7 | Bcr-Abl , ACK , AChR |
GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively. | |||
T22553 | Adaphostin | 1-Adamantyl 4-((2,5-Dihydroxybenzyl)Amino)Benzoate,NSC 680410 | Bcr-Abl |
Adaphostin (NSC-680410) is a p210Bcr/Abl tyrosine kinase inhibitor with IC50 of 14 μM. | |||
T16545 | Pivanex | Pivalyloxymethyl butyrate,AN-9 | Apoptosis , HDAC , Bcr-Abl |
Pivanex (Pivalyloxymethyl butyrate) is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis. | |||
T26625 | AN-019 | NRC-AN-019,NRC-019 | Bcr-Abl |
AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer. | |||
T72958 | BCR-ABL-IN-7 | Bcr-Abl | |
BCR-ABL-IN-7 is a WT and T315I mutant ABL kinase inhibitor.BCR-ABL-IN-7 potently inhibits WT and T315I mutant ABL kinase activity.BCR-ABL-IN-7 can be used in chronic myelogenous leukemia (CML) research. | |||
T22859 | Imatinib hydrochloride | Others | |
Imatinib is a multi-target inhibitor of v-Abl, c-Kit, and PDGFR (IC50: 0.6 μM, 0.1 μM, and 0.1 μM, respectively). Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs), and... | |||
T71313 | BVB-808 | ||
BVB-808 is a selective Jak2 type 1 inhibitor. Janus kinases are critical components of signaling pathways that regulate hematopoiesis. Mutations of the non-receptor tyrosine kinase JAK2 are found in many BCR-ABL-negative... |